EPHX2 and cancer: The assessment of EPHX2 mutations, copy number alteration (CNA), and methylation conditions in pan‐cancer indicated that EPHX2 genomic modifications were higher than 20% in BLCA tumor samples, with “deep deletion” being the most common type (Figure 6A).